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Cisplatin +/− rucaparib after preoperative chemotherapy in
patients with triple-negative or BRCA mutated breast cancer
Maitri Kalra1, Yan Tong2, David R. Jones1, Tom Walsh3, Michael A. Danso4, Cynthia X. Ma5, Paula Silverman6, Mary-Claire King 3,
Sunil S. Badve1, Susan M. Perkins2 and Kathy D. Miller 1✉
Patients with triple-negative breast cancer (TNBC) who have residual disease after neoadjuvant therapy have a high risk of
recurrence. We tested the impact of DNA-damaging chemotherapy alone or with PARP inhibition in this high-risk population.
Patients with TNBC or deleterious BRCA mutation (TNBC/BRCAmut) who had >2 cm of invasive disease in the breast or persistent
lymph node (LN) involvement after neoadjuvant therapy were assigned 1:1 to cisplatin alone or with rucaparib. Germline mutations
were identified with BROCA analysis. The primary endpoint was 2-year disease-free survival (DFS) with 80% power to detect an HR
0.5. From Feb 2010 to May 2013, 128 patients were enrolled. Median tumor size at surgery was 1.9 cm (0–11.5 cm) with 1 (0–38)
involved LN; median Residual Cancer Burden (RCB) score was 2.6. Six patients had known deleterious BRCA1 or BRCA2 mutations at
study entry, but BROCA identified deleterious mutations in 22% of patients with available samples. Toxicity was similar in both
arms. Despite frequent dose reductions (21% of patients) and delays (43.8% of patients), 73% of patients completed planned
cisplatin. Rucaparib exposure was limited with median concentration 275 (82–4694) ng/mL post-infusion on day 3. The addition of
rucaparib to cisplatin did not increase 2-year DFS (54.2% cisplatin vs. 64.1% cisplatin+ rucaparib; P= 0.29). In the high-risk post
preoperative TNBC/BRCAmut setting, the addition of low-dose rucaparib did not improve 2-year DFS or increase the toxicity of
cisplatin. Genetic testing was underutilized in this high-risk population.
npj Breast Cancer            (2021) 7:29 ; https://doi.org/10.1038/s41523-021-00240-w
INTRODUCTION
Triple-negative breast cancer (TNBC) lacks expression of estrogen
(ER), progesterone (PR), and human epidermal growth factor
receptor-2 (HER2) receptors, accounts for ~15–20 percent of all
breast cancers, and is more aggressive than other subtypes1.
Though not synonymous, TNBC is classified as basal-like breast
cancer via cDNA microarray ~75% of the time2,3. Approximately
75–80% of breast cancers that develop in women harboring
deleterious BRCA1 mutations have a triple-negative phenotype
and basal-like gene expression. The correlation between TNBC,
basal-like breast cancer, and BRCA1 mutations suggests a similar
underlying molecular pathogenesis that could be exploited
therapeutically.
Inhibition of poly(ADP-ribose) polymerase (PARP) leads to
impaired single-strand break (SSB) repair, ultimately leading to
double-strand breaks (DSB) in replicative cells4,5. In BRCA wild-type
cells, the DSBs are repaired via homologous recombination (HR),
limiting damage. Conversely, in BRCA-deficient cells, HR is
impaired and alternative pathways lead to complex rearrange-
ments, loss of effective repair, and cell death (“synthetic lethality”).
Clinical trials have demonstrated objective responses and/or an
increased progression-free survival (PFS) with PARP inhibitor
monotherapy in patients with germline BRCA1 or BRCA2 muta-
tions6–10. The same BRCA-deficient defect in HR increases
sensitivity to DNA-damaging chemotherapy compared to
microtubule-acting agents. For example, response and PFS were
superior with carboplatin compared to docetaxel in patients with
mutated BRCA but not in patients with TNBC and intact BRCA11.
Neoadjuvant chemotherapy not only increases breast conserva-
tion but also provides an in vivo chemosensitivity assay, offering an
ideal platform for clinical research. Although many will experience
tumor shrinkage, only about ~25–45% of patients with TNBC will
achieve a pathologic complete response (pCR), defined as the lack
of invasive disease in the breast and regional lymph nodes at the
time of surgery, with chemotherapy alone. Long-term follow-up of
neoadjuvant studies consistently demonstrates significantly
improved survival in patients who achieve a pCR compared to
those with residual disease12, particularly in those with TNBC13,14.
Those with substantial residual TNBC (Miller–Payne classification 1
or 215 or RCB classification II or III16) have an inferior prognosis with
only 35–40% remaining free of recurrence at 2 years. This high-risk
group represents both an unmet medical need and an opportunity
to accelerate the testing of novel agents in the early disease
setting.
Based on the hypothesis that TNBC has an exploitable DNA
damage repair defect similar to that seen in patients with the
germline BRCA mutation, we undertook this randomized phase II
trial to determine efficacy and safety of cisplatin alone or with
rucaparib in patients with TNBC/BRCAmut who had substantial
residual disease after standard neoadjuvant chemotherapy.
RESULTS
Patient population
From Feb 2010 to May 2013, 128 patients (intent-to-treat
population) were enrolled in safety cohort 2 (n= 6) and the
randomized portion (n= 122) of the study (Fig. 1). Patient
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characteristics are detailed in Table 1. Treatment arms were
generally well balanced with a median age of 47.5 years (range
21–75 years), median residual tumor 1.9 cm, and involvement of
one regional lymph node. The median RCB classification (graded as
described in ref. 16) was 2.6 in cisplatin alone arm and 2.7 in the
cisplatin plus rucaparib arm (median RCB score 53 vs. 59). Three
patients in each arm had weak ER+ tumors. Anthracycline
exposure was more frequent in patients randomized to cisplatin
(66.2% vs. 47.6%) but nearly all patients had received a taxane. Few
patients had received carboplatin.
Efficacy
The addition of rucaparib to cisplatin did not increase 2-year DFS
(cisplatin 54.2% (95% CI: 39.8%, 66.6%) vs. cisplatin+ rucaparib
64.1% (95% CI: 50.3%, 75.0%); P= 0.29) or 5-year DFS (38.3% (95%
CI: 24.6%, 51.8%) vs. 50.1% (95% CI: 35.5%, 63.0%); P= 0.25,
Fig. 2a).
Drug exposure and toxicity
Overall more than two-thirds of patients completed the planned
four cycles of cisplatin (69.2% cisplatin, 77.8% cisplatin+ rucaparib),
and median cisplatin dose intensity was similar in both arms
(73.1 mg/m2 vs. 73.5mg/m2). Cisplatin dose reduction due to
toxicity, most commonly myelosuppression, was similar in both
groups (18.5% vs. 23.8%). Only one patient in each arm reported
grade 4 neutropenia (Table 2). In contrast, only 50.8% of the
patients completed the planned 24 weeks of rucaparib main-
tenance. Eleven patients declined to start maintenance therapy,
often due to the cost of frequent travel to the study site or a desire
for early reconstruction. The most common reason for early
discontinuation in patients starting maintenance therapy was
disease progression (n= 10). Rucaparib dose was reduced in eight
patients, four (6.3%) due to toxicity and four (6.3%) due to dosing
error. Rucaparib dose delays were common (76.2%); 31 patients
(49.2%) required rucaparib dose delays due to toxicity, most
frequently due to fatigue; 25.4% due to scheduling constraints
(holiday clinical closure, travel, etc.).
Pharmacokinetic data were available from 60 patients treated
with rucaparib (6 from safety cohort 2 and 54 randomized to
cisplatin+ rucaparib). Based on the in vitro IC90 against the
target, adjusted for protein binding, a sustained plasma concen-
tration of >5.9 ng/mL was projected to be needed in humans to













Never Treated - 8
AE/Side Effects/ - 4
Disease progression during treatment - 2
y Start - 6
Lost to Follow-up - 1






Never Treated - 1
AE/Side Effects/ s - 3
Disease progression during treatment - 10
y Start - 4
Lost to Follow-up - 0
Treatment Completed Per Protocol - 45
Off study
Death due to other causes - 1
Death due to progressive disease - 24
st to/refused follow-up - 16
Sy c deterio on - 0
Protocol defined follow-up complete - 19
Off study
Death due to other causes - 1
Death due to progressive disease - 22
st to/refused follow-up - 7
Sy c deterio on - 3
Protocol defined follow-up complete - 13 





Arm B: Cis Rucaparib
N = 57
Fig. 1 Consort diagram detailing the disposition of all patients enrolled. Patients enrolled in the safety cohort 1 are not reported in detail.
Patients enrolled in safety cohort 2 are combined with patients randomized to Arm B for all intent-to-treat analyses.
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concentration 282 ng/mL (range 82–2403mg/mL) post-infusion
on day 3. Of the 52 patients who received maintenance rucaparib,
16 received only IV rucaparib, 8 began IV and switched to oral
when the oral formulation became available, and 28 received only
oral rucaparib maintenance. During IV maintenance, the pre-dose
sample was below the LLOQ (0.1 ng/ml) for rucaparib in 82% at
week 1 and 37.5% at week 5. During oral maintenance, pre-dose
rucaparib was below the LLOQ in 70% at week 1 and 23% at
week 5.
Germline genetics
Only six patients were known to have deleterious BRCA mutations
(two BRCA1 and four BRCA2) prior to study entry. Germline DNA,
available in 101 consenting patients, was analyzed for the
presence of deleterious mutations in BRCA1 and BRCA2, as well
as 21 other genes known to increase the risk of breast cancer
(BROCA)17,18. This testing identified germline mutations in 22
patients, including 8 BRCA1, 12 BRCA2, and 2 BRIP1. DFS results
were similar in the subset of 22 patients with deleterious
mutations (2-year DFS for cisplatin 69.2% (95% CI: 37.3%, 87.2%)
vs. 65.6% (95% CI: 15.7, 90.9%) for cisplatin+ rucaparib; P= 0.88,
Fig. 2b). Combining treatment arms, we found no difference in
outcome in patients with versus without deleterious BRCA
mutations (2-year DFS 68.6% (95% CI: 42.6%, 84.6%) cisplatin vs.
58.4% (95% CI: 46.4%, 68.7%) cisplatin+ rucaparib; P= 0.44, 5-
year DFS 36.4% (95% CI: 14.6%, 58.7%) cisplatin vs. 47.4% (95% CI:
34.9%, 58.9%) cisplatin+ rucaparib, P= 0.41).
DISCUSSION
The high risk of recurrence in patients with TNBC/BRCAmut who
have residual disease after neoadjuvant therapy provides a robust
clinical laboratory for testing new therapies. We hypothesized that
a DNA damage repair defect would lead to benefit from cisplatin,
and that the addition of the PARP inhibitor rucaparib would
amplify that benefit. This is a negative trial—the addition of low-
dose rucaparib did not improve 2-year DFS. Unfortunately, our
study had several limitations that leave the original hypothesis
largely unanswered.
First, we lacked an appropriate contemporary control arm. Our
study was conducted well before the results of the CreateX trial
which suggested benefit for adjuvant capecitabine in this patient
population19. Randomization to a “no adjuvant therapy” control
was considered but ultimately rejected. Provider surveys and
practice pattern data suggested that nearly half of all patients
eligible for our trial received adjuvant therapy in the absence of
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13 20 11 17.5
Asian 1 1.5 3 4.8
Not reported/
unknown
2 3.1 3 4.8
Ethnicity Hispanic
or Latino
6 9.2 3 4.8
Non-Hispanic 57 87.7 53 84.1
Not reported/
unknown
2 3.1 7 11.1
Age Median 48 47
Range 27–69 21–75
ECOG PS 0 52 80 52 82.5
1 13 20 11 17.5
Tumor size at diagnosis Median 2.8 cm 3.9 cm
Range 1.2–7.0 1.3–5.0
ER Negative 61 93.8 60 95.2
Positive 3 4.6 3 4.8
Unknown 1 1.5 0 0
PR Negative 62 95.4 60 95.2
Positive 2 3.1 3 4.8
Unknown 1 1.5 0 0
HER2 Negative 64 98.5 62 98.4
Positive 1 1.6
Unknown 1 1.5 0 0
Germline mutation
known prior to entry
BRCA1 No 64 98.5 62 98.4
Yes 1 1.5 1 1.6
BRCA2 No 63 96.9 61 96.8
Yes 2 3.1 2 3.2
Neoadjuvant chemotherapy
Anthracycline Yes 43 66.2 30 47.6
No 22 33.8 33 52.4
Taxanes Yes 60 92.3 56 88.9
No 5 7.7 7 11.1
Carboplatin Yes 0 0 6 9.5
No 65 100 57 90.5
Bevacizumab Yes 1 1.5 0 0
No 64 98.5 63 92.1
Residual disease
Tumor size at surgery
(cm)b
N 54 57
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aIncludes patients in safety cohort 2 (n= 6) and all patients randomized to
Arm B (n= 57). Characteristics from patients in safety cohort 1 are not
reported.
bTumor size could not be accurately measured in 11 patients.
cEleven patients underwent sentinel node biopsy prior to neoadjuvant
chemotherapy and did not have additional nodes resected at the time of
definitive surgery.
dRCB could not be calculated in 16 patients.
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supportive data and with a variety of different regimens, limiting
acceptance of a no-treatment control arm and complicating
analysis. As we hypothesized a favorable interaction between
cisplatin and rucaprib, a two-by-two factorial design was not
appropriate. A three-arm trial would have been scientifically
superior but the sample size was prohibitive. Recognizing that
would result would not be definitive, we compensated for the lack
of control by selecting a high-risk population and targeting a large
improvement in efficacy.
Second, neoadjuvant chemotherapy was not standardized
increasing the heterogeneity of our patient population. Some
may be surprised that only half of the patients enrolled in our trial
received anthracycline-based neoadjuvant therapy. The use of
anthracyclines in early-stage breast cancer was influenced by a
prominent national debate with well-respected leaders arguing
against and for use of anthracycline-based regimens, leading to
wide regional variation in the use of anthracyclines. That variation
is reflected by our patient population. Similarly, we allowed
patients who had received carboplatin in the neoadjuvant setting
to enroll, potentially limiting the benefit of cisplatin-based
therapy. Our major interest was in the potential synergy of the
combination, which we hypothesized may overcome resistance to
DNA-damaging chemotherapy alone. As few patients in our trial
had received neoadjuvant carboplatin, their impact is minimal.
Third, 2-year DFS was better in our patients than we had
predicted, reducing the power of our study. Several factors may
have contributed to this improved outcome. Over time patients
with the less extensive disease were treated in the neoadjuvant
setting. As the initial disease burden did not impact eligibility, we
did not collect the data on the clinical stage at presentation to
evaluate the impact of this shift in practice. We also included
patients with a pCR in the breast and residual nodal disease.
Several of those patients had the only microscopic residual nodal
disease and would have been classified as RCB I with an excellent
prognosis. Finally, in the absence of a control arm, we can not
deduce or exclude the potential benefits from cisplatin
monotherapy.
Finally, the enthusiasm for PARP inhibitors a decade ago,
spurred by the high-profile presentation of data from a phase II
trial of the putative PARP inhibitor iniparib20, accelerated protocol
development. We rushed to activation while the initial dose-
finding studies of rucaparib were ongoing and before the final oral
formulation was available. While our design protected patient
safety, we did not fully consider the potential negative implica-
tions of early activation. In this case, the dose of rucaparib used in
a) Disease-free survival












Cisplatin + Rucaparib (Arm B)













Number of pts at risk
Arm A 65 37 27 23 18 13 0











Cisplatin + Rucaparib (Arm B)













Number of pts at risk
Arm A 14 11 9 7 5 4 0
Arm B 8 6 3 2 2 1 1
Fig. 2 Disease-free survival. a All patients in the intent-to-treat
analysis. Median DFS (38.8 months vs. not reached, P= 0.24) and 5-
year DFS (38.3% vs. 50.1%; P= 0.24) were similar in both treatment
groups. b Patients with deleterious germline BRCA1 or BRCA2
mutations (n= 22). Median DFS (19.5 vs. 13.8 months, P= 0.99)




(N= 65) N (%)
Cisplatin+ rucaparib (N=
63)a N (%)
NCI-CTC grade 2 3 4 2 3 4
Neutropenia 16 (25) 11 (17) 0 13 (21) 16 (25) 1 (2)
Neutropenic fever 1 (2) 0 0 1 (2) 0 0
Anemia 5 (8) 0 0 7 (11) 0 0
Thrombocytopenia 2 (3) 0 0 0 2 (3) 0
Nausea 13 (20) 0 0 16 (25) 3 (5) 0
Anorexia 3 (5) 0 0 7 (11) 0 0
Fatigue 14 (22) 3 (5) 1 (2) 11 (17) 6 (10) 0
Tinnitus 16 (25) 1 (2) 0 12 (19) 1 (2) 0
Nephropathy 1 (2) 0 0 2 (3) 0 0
Neuropathy 1 (2) 0 0 3 (5) 1 (2) 0
Vomiting 5 (8) 0 0 7 (11) 3 (5) 0
Hepatic abnormality 0 1 (2) 1 (2) 0 3 (5) 0
Rash 2 (3) 0 0 2 (3) 0 0
Headache 2 (3) 0 0 5 (8) 0 0
Dysgeusia 3 (5) 0 0 1 (2) 0 0
Worst toxicity per patient according to NCI-CTC v 3.0.
aIncludes toxicity reported during rucaparib maintenance.
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our study (100 mg orally once a week) is substantially less than the
recommended phase II dose (600mg orally twice daily)21,22
currently used for maintenance therapy in patients with recurrent
ovarian cancer. Our pharmacokinetic analysis further emphasizes
the low dosage used in our trial, as more than a quarter of the
patients had levels below the lower limit of detection with both
intravenous and oral formulations. While rucaparib concentrations
during combined therapy were above the level predicted to
inhibit PARP in humans (>5.9 ng/mL), sustained PARP inhibition
was almost certainly not achieved. The relative lack of myelosup-
pression, a pharmacodynamic hallmark of effective PARP inhibi-
tion, is consistent with the limited rucaparib exposure. Thus it is
unlikely that the doses we used were sufficient to meaningfully
inhibit PARP, leaving our initial hypothesis largely unanswered.
Despite these limitations, our trial has several important
findings. First, germline genetic testing was, and based on recent
reports by others23–26 remains, woefully underused. National
Comprehensive Cancer Network (NCCN) guidelines recommend
that all patients younger than 60 years with TNBC be offered
genetic testing irrespective of family history25. With a median age
of 47 years, over half of our patients would have met NCCN testing
criteria, yet only six patients were known to have deleterious
mutations at study entry. Fully two-thirds of the BRCA mutations
identified by BROCA analysis were not identified during routine
clinical care. We did not expect such sparse use of genetic testing
and thus did not collect the data to determine if testing was not
offered, not accepted, or not performed to due financial
constraints. Given the impact of identifying a germline mutation,
enhanced education26, and ongoing clinical vigilance to identify
patients meeting testing guidelines is clearly needed. As a
substantial proportion of women with breast cancer carrying
germline pathogenic variants do not qualify for testing by NCCN
criteria, expansion of current testing guidelines should be
considered27.
In addition, biologic specimens collected in our study have
yielded other important insights28,29. Analysis of matched somatic
genomes pre-/post-neoadjuvant chemotherapy revealed the
chaotic acquisition of copy gains and losses, including amplifica-
tion of prominent oncogenes. Gene expression data revealed
depletion of immune signaling, which was corroborated by
decreases in tumor-infiltrating lymphocytes in post-neoadjuvant
samples. We also found enrichment of actionable regulators of
stem cell-like behavior and a poor prognosis associated with
somatic gains in 18q, likely driven by putative upregulation of
TGFß signaling through the signal transducer SMAD2.
Recognizing that TNBC is heterogenous at the genomic level30–32,
a single therapeutic approach is less likely to be successful.
Consequently, we designed a follow-up study to exploit targetable
alterations found by sequencing residual disease. BRE12-158
(NCT02101385) randomized 196 TNBC patients with residual
disease after neoadjuvant therapy to genomically directed therapy
versus treatment of physician choice (capecitabine recommended
based on the CreateX trial data). PFS results are expected within
the next 12–18 months. Two ongoing national trials evaluate the
impact of other therapeutic approaches. EA1131 (NCT02445391)
follows our original hypothesis, comparing adjuvant platinum
therapy (cisplatin or carboplatin) to capecitabine. Though all
patients with TNBC and at least 1 cm of residual disease in the
breast are eligible, the primary endpoint focuses on those with
basal-like breast cancer. In contrast, S1418 (NCT02954874)
evaluates the immune checkpoint inhibitor pembrolizumab,
hoping to reverse the negative impact of immune depletion seen
in residual disease specimens. Both trials are actively enrolling




Patients with Stage II-III TNBC/BRCAmut who had undergone neoadjuvant
chemotherapy with an anthracycline and/or taxane-containing regimen
were eligible if they had the substantial residual disease at the time of
definitive surgical resection. We defined substantial residual disease as any
one of the following: Miller–Payne class 1 or 2, RCB II or III, at least 2 cm of
invasive disease in the breast, or persistent involvement of at least one
axillary lymph node. Neoadjuvant cisplatin was prohibited but the
incorporation of carboplatin as a component of neoadjuvant therapy
was allowed. ER status was determined by local pathology assessment;
patients with low levels of ER and/or PR expression (Allred Score ≤ 2 or
<5% weak staining) were allowed. Patients with known deleterious BRCA1
or BRCA2 mutations were eligible with any degree of ER expression, but
patients with HER2+ tumors were not eligible regardless of BRCA status.
Patients who had breast-conserving surgery received adjuvant whole-
breast radiation therapy. Postmastectomy radiotherapy was required for
patients with primary tumor ≥5 cm or involvement of four or more lymph
nodes. Postmastectomy radiation in other situations was left to the
treating physician’s discretion. All radiation therapy was completed prior to
study entry. Patients were required to have an ECOG PS 0 or 1 with
adequate renal, bone marrow, and cardiac function. The protocol was
approved by the Institutional Review Board, and all patients gave written
informed consent prior to study enrollment.
Treatment plan
As there was no prior experience with cisplatin and rucaparib in
combination, the study began with two sequential safety cohorts to
exclude prohibitive toxicity (Fig. 1). All patients received cisplatin 75mg/m2
on day 1 every 21 days for four cycles. Cohort 1 (n= 7) received rucaparib
16mg IV on days 1–3 in cycle 1, and in the absence of dose-limiting
toxicity (DLT), 24 mg IV on days 1–3 in cycles 2–4. Cohort 2 (n= 6) received
rucaparib 24mg IV on days 1–3 in cycle 1, and in the absence of DLT,
30mg IV on days 1–3 in cycles 2–4 (considered “full” dose rucaparib at the
time). Patients in the safety cohorts were evaluated clinically and with
laboratory assessments weekly during cycles 1 and 2. Cohort 2 began only
after ≤1 of six patients in cohort 1 experienced DLT during the first two
cycles of therapy. After ≤1 of six patients in cohort 2 experienced DLT
during cycles 1 and 2, subsequent patients were randomized to one of two
treatment arms. Arm A received cisplatin monotherapy. Arm B received
cisplatin+ rucaparib (24mg IV for cycle 1, 30mg IV for cycles 2–4 as in
safety cohort 2) on days 1–3 every 21 days for four cycles followed by
maintenance rucaparib for 24 weeks (30 mg IV once weekly). An oral
rucaparib formulation became available when accrual was ~70% complete.
At that point, the study was amended to use the oral formulation (100mg
once weekly, predicted to yield similar rucaparib exposure as 30mg IV
once weekly) during maintenance therapy only; all patients received the IV
formulation for cycles 1–4. Optimal supportive care including antiemetics,
hydration, antibiotics, and blood transfusion was permitted as clinically
indicated and according to institutional guidelines. Prophylactic use of
white blood cell growth factors was not allowed unless used in accordance
with ASCO guidelines.
Toxicity was assessed based on the National Cancer Institute Common
Toxicity Criteria (NCI-CTC) version 3.0. Dose modifications were based on
nadir blood counts and interval toxicity, considering each drug individu-
ally. Cisplatin dose was reduced 25% for neutropenic fever, platelets less
than 75,000/mm3, neutrophil count less than 1500/mm3 for >1 week,
creatinine more than 1.5 times upper limit of normal (ULN), and grade 3 or
more hepatic toxicity. Rucaparib dose was not adjusted for the first
episode of neutropenic fever, reduced by 25% for a second episode, and
discontinued for a third episode. Rucaparib dose was held and then
resumed at the same dose upon recovery for neutrophil count <1500/mm3
and platelet count less than 100,000/mm3. Rucaparib was discontinued for
any other grade 3 or 4 toxicity lasting >3 weeks. Upon completion of
protocol therapy, patients were followed clinically every 4 months
throughout years 1–2, then every 6 months for years 3–5. Annual breast
imaging was required in all patients with remaining native breast tissue;
consistent with NCCN33 and ASCO guidelines34, no other imaging or
laboratory assessments were required during follow-up.
Correlative studies
Archived tumor samples from the definitive surgery were banked for future
analyses; when available a sample from the pre-neoadjuvant chemotherapy
M. Kalra et al.
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diagnostic biopsy was retrieved and banked. Analyses of available paired
(pre–post-neoadjuvant chemotherapy) tumor samples have been reported
separately28.
Blood for limited pharmacokinetic (PK) analyses was obtained pre-dose
and 5min (+/−5min) prior to the end of rucaparib infusion on cycle 1 day
3, cycle 2 day 3, and then weeks 1 and 5 of maintenance therapy. In
patients switching from the IV to oral formulation during maintenance
therapy, PK sampling was repeated 2 h post-dosing during the 1st and 5th
week of oral therapy. Plasma rucaparib concentration was quantified using
midazolam as the internal standard, liquid-liquid extraction, and HPLC-MS/
MS (ABSciex3200, Applied Biosystems). Rucaparib and midazolam were
separated by gradient mobile phase (acetonitrile: 0.1% formic acid) and
HPLC using a C8 column (Restek 5 µm 150 × 4.6 mm). The Q1/Q3
transitions for rucaparib and midazolam were 324/293 and 326/291,
respectively. The lower limit of quantification (LLOQ) was 0.1 ng/mL using
100 µL of plasma.
Consenting patients (n= 101) provided a sample for germline genetic
testing. DNA extracted from blood was sequenced using BROCA, a
targeted capture and massively parallel sequencing test developed at the
University of Washington17. Twenty-three genes were analyzed for this
trial, including BRCA1, BRCA2, ATM, ATR, BAP1, BARD1, BRIP1/FANCJ, CDH1,
CHEK1, CHEK2, FAM175A/ABRAXAS, FANCM, MRE11A, NBN, PALB2/FANCN,
PTEN, RAD51B, RAD51C, RAD51D, RINT1, SLX4/FANCP, TP53, and XRCC2. For
each gene, the entire locus was sequenced, including all coding exons,
complete 5′- and 3′-untranslated regions (UTRs), all introns (after removing
Alu repeats), and 5–15 kb flanking transcription start and stop sites.
Sequencing reads were aligned to human reference genome hg19.
Variants were identified by GATK and Pindel after indel realignment and
base quality recalibration. Single nucleotide variants and small insertion-
deletion variants (indels) were identified. Copy number variants (CNVs)
were identified using the in-house pipeline of the King lab35. Mutations
potentially leading to splicing errors were included only if experimental
validation of the effect had been previously shown using RNA isolated
from patients’ blood. Missense mutations were included only if proven
experimentally to be damaging.
Sample size and statistical analyses
The primary endpoint was 2-year DFS, including all local–regional
recurrences, distant recurrences, and deaths from any cause as DFS
events. Secondary clinical objectives included safety, 1-year and 5-year
DFS. We hoped to detect an improvement in 2-year DFS from 40% in the
control arm16 to 63.2% in the rucaparib arm (corresponding to an HR= 0.5)
with 80% power using a one-sided log-rank test at the 0.10 significance
level. This design required 38 events. Assuming an accrual over
13–18 months and an exponential survival, 102 patients were required
for the primary analysis. The total sample size was increased to 135 to
accommodate the two safety cohorts (n= 13) and to account for drop-outs
(estimated at 20%). Patients in safety cohort 2 were combined with
patients randomized to Arm B for analysis; patients enrolled in cohort 1 are
not reported in detail and were not included in efficacy analyses.
DFS was compared between the two treatment arms using an un-
stratified Kaplan–Meier analysis with a log-rank test. A specific comparison
of 2-year DFS was made using a two-sample test based on the
complementary log–log transformation as suggested in Klein et al.36.
Similar methods were used to compare 2-year DFS for patients with versus
without germline BRCA mutations. Limited PK sampling was included to
complement ongoing PK analyses in other rucaparib trials, and thus only
descriptive analyses were planned. The archived tumor and germline DNA
samples were used to explore potential correlates of recurrence and
sensitivity to PARP inhibition.
The Hoosier Cancer Research Network (HCRN) compiled data summary
reports for this trial and submitted these reports monthly to the lead
investigator; quarterly data summaries were reviewed by the Indiana
University Melvin and Bren Simon Cancer Center (IUSCC) Clinical Trial
Monitoring Committee.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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